Latest studies
- RecruitingPHASE3
Global Trial in APG2575 for Patients With CLL/SLL
This study is looking into a new treatment called lisaftoclax for people with a type of blood cancer called CLL/SLL. It compares adding lisaftoclax to an existing BTK inhibitor treatment versus just using the BTK inhibitor alone, for patients who have already been on BTK inhibitors.
CLL/SLLBelgium - Enrolling by invitationPHASE3
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
This study looks at a new drug, LP352, for children and adults with a type of epilepsy called Developmental and Epileopathic Encephalopathy (DEE). It checks how safe and effective the drug is over a longer period for those who have already started treatment in previous studies.
Developmental and Epileptic EncephalopathyBelgium - Active not recruitingPHASE3
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
This study looks at the long-term safety of a treatment called astegolimab for people with a lung condition called COPD. It's for people who have already taken part in previous studies of this drug.
Chronic Obstructive Pulmonary DiseaseBelgium - Active not recruitingPHASE3
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
This study is looking into the long-term effects and safety of a medicine called mirikizumab for people with Crohn's disease. Participants have already taken part in a related study, and this new study will help us understand how the medicine works over a longer period.
Crohn's DiseaseBelgium - RecruitingPHASE3
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
This study is testing a drug called pridopidine for people with Amyotrophic Lateral Sclerosis (ALS), also known as Motor Neurone Disease. We want to see if pridopidine can slow down how ALS progresses and if it's safe to use. Participants will take the drug or a dummy pill daily.
Amyotrophic Lateral SclerosisBelgium - RecruitingPHASE2, PHASE3
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
This study is testing a new medicine, CSL300, for adults with advanced kidney disease on dialysis. It aims to see if CSL300 can improve heart health and is safe, especially for those with existing heart conditions or diabetes.
End Stage Kidney DiseaseBelgium - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
This study is testing a new medication called Tulisokibart for people with moderate to severe Crohn's disease. Researchers want to see if it's safe and effective in reducing symptoms and improving the gut lining. It involves different ways of giving the medicine compared to a dummy treatment.
Crohn's DiseaseBelgium - Active not recruitingPHASE3
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
This study looks at a new medicine called risankizumab for Crohn's disease. We're checking how well it works and if it's safe for people who have already started treatment. It's like a follow-up to see how different doses work and how people feel over time.
Crohn's DiseaseBelgium - RecruitingPHASE3
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
This study is looking for better ways to treat advanced kidney cancer that has come back after earlier treatment. Researchers want to see if a new combination of medicines, belzutifan and zanzalintinib, works better than a standard medicine, cabozantinib, at shrinking the cancer.
Renal Cell CarcinomaBelgium - Active not recruitingPHASE2, PHASE3
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
This study looks at a new medicine called guselkumab for adults with moderately to severely active Crohn's disease. Researchers want to see how well it works and if it's safe compared to other treatments or a dummy medicine.
Crohn's DiseaseBelgium - RecruitingPHASE3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
This study is testing a new drug, rilvegostomig, against a standard treatment, pembrolizumab, for advanced lung cancer. It's for people whose cancer has spread and has high levels of a specific marker called PD-L1. The aim is to see which treatment works better and is safer.
Carcinoma, Non-Small Cell LungBelgium - RecruitingPHASE3
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
This study is for people with advanced bowel cancer that has spread and has a specific gene change called KRAS p.G12C. It compares a new combination of treatments to standard treatment to see if it can better stop the cancer from growing.
Metastatic Colorectal CancerBelgium - RecruitingPHASE2
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
This study is testing a new medicine, SAT-3247, for boys aged 7-9 with Duchenne muscular dystrophy. We want to find the best dose, see if it's safe, and check if it helps. Some boys will get the real medicine, others a dummy medicine.
Duchenne Muscular DystrophyDuchenneDMDNeuromuscular DiseasesBelgium - RecruitingPHASE2, PHASE3
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
This study is testing a new medicine, icotrokinra, for people in the UK with moderately to severely active Crohn's disease. Researchers want to see if it helps reduce symptoms and if it's safe to use, compared to a dummy medicine.
Crohn DiseaseBelgium - RecruitingPHASE3
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
This study compares a new treatment, TAR-210, with standard chemotherapy for high-risk bladder cancer that hasn't spread to the muscle. It aims to see which treatment best prevents the cancer from returning or getting worse.
Non-Muscle Invasive Bladder NeoplasmsBelgium - RecruitingPHASE2
Pan Tumor Rollover Study
This study looks at the long-term safety of different cancer treatments, including nivolumab, alone or combined with other medicines. It's for people with various types of cancer who are already receiving treatment in a related study, aiming to see how these treatments work over time.
CancerBelgium - Active not recruitingPHASE3
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
This study compares two treatments, risankizumab and ustekinumab, for adults with moderate to severe Crohn's disease. Researchers want to see which treatment works best to reduce Crohn's symptoms. Both treatments are given initially by IV, then by injection.
Crohn's Disease (CD)Belgium - RecruitingPHASE3
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
This study is testing a new drug, Telisotuzumab Vedotin, against a standard treatment, Docetaxel, for advanced non-small cell lung cancer. It aims to see if the new drug works better and is safe for adults who have already had treatment.
Non Small Cell Lung CancerBelgium - Active not recruitingPHASE3
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
This study looks at a new medicine called upadacitinib for adults with Crohn's disease. It checks how well it works and if it's safe over a long time for people who have already started treatment in previous studies. The aim is to see if it can help manage Crohn's.
Crohn's DiseaseBelgium - Active not recruitingPHASE3
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
This study is testing a new medicine called lutikizumab for people aged 12 and over with moderate to severe hidradenitis suppurativa (HS). It compares the new medicine to a dummy treatment (placebo) to see if it helps reduce HS symptoms and is safe.
Hidradenitis SuppurativaBelgium - Active not recruitingPHASE3
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
This study compares a new medicine, upadacitinib, with a sugar pill (placebo) and an existing medicine, adalimumab, for adults with rheumatoid arthritis. It looks at how well these treatments work and if they are safe when methotrexate isn't enough on its own.
Rheumatoid ArthritisBelgium - Active not recruitingPHASE3
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
This study looks at the long-term effects and safety of a drug called mirikizumab for people with moderate to severe ulcerative colitis. It can last up to three years, with a chance to continue treatment afterward.
Ulcerative ColitisBelgium - Recruiting
To Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery.
This study looks at how well a special scan, called PET-CT, works on removed cancer tissue. It compares these scans with lab results and patient health over time to see if this technology can improve cancer care and treatment decisions.
Prostate CancersBreast CancerHead and Neck CancerCancerBelgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (PROSPERO)
This study is testing a new medicine called Tozorakimab for people with severe COPD. It aims to see if Tozorakimab can reduce flare-ups and is safe to use long-term, compared to a dummy medicine.
Chronic Obstructive Pulmonary Disease (COPD)Belgium - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Multiple-Ascending-Dose Study of MK-4318 in Healthy Participants
This study is testing a new medicine called MK-4318 in healthy people. The main goal is to see how safe the medicine is and how the body handles different doses of it. Researchers hope this medicine could one day help with pain.
PainBelgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
A MULTICOHORT, OPEN LABEL, PHASE 2 STUDY OF BOTENSILIMAB (AGEN1181) FOR TREATMENT OF ADVANCED MELANOMA REFRACTORY TO PRIOR CHECKPOINT INHIBITOR THERAPY
This study is testing new medicines, botensilimab and balstilimab, for adults with advanced melanoma. These are cancers that have not responded to previous treatments. We want to see if the new medicines can shrink the cancer.
Advanced melanoma refractory to prior checkpoint inhibitor therapyBelgium - Ongoing, recruitingPhase II and Phase III (Integrated)
A Phase 2b/3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants
This study is looking at a new medicine, MK-1654, to help protect babies from a common chest infection called RSV. It will check if the medicine works well and if it's safe for both premature and full-term babies.
Prevention of RSVBelgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Open-label safety study in adults and adolescents with haemophilia A with and without FVIII inhibitors switching directly from emicizumab prophylaxis to NNC0365-3769 (Mim8) prophylaxis.
This study looks at a new medicine called denecimig for people with haemophilia A. It checks how safe it is when people switch from a different medicine (emicizumab). Doctors want to see if there are any new health problems when people start taking denecimig.
Haemophilia A with or without coagulation factor VIII (FVIII) inhibitors.Belgium - Ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
First-in-human study of SAR445611 in healthy adult participants
This early-stage study is testing a new medicine called SAR445611 for the first time in healthy adult volunteers. The aim is to see how safe it is and how it works in the body, which could help people with immune system problems in the future.
Immune system diseasesBelgium - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of single ascending doses of 4P-004 versus placebo injected in the Target Knee Joint of Patients with grade 2 to 4 osteoarthritis on the Kellgren and Lawrence severity index.
This study is looking at a new medicine called 4P-004 for knee osteoarthritis. Scientists want to see if it's safe, how well the body handles it, and how it moves through the body after a single injection into the knee. This is an early-stage study.
Knee osteoarthritisBelgium - Ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE ASCENDING DOSES OF REGN7999, A TMPRSS6 ANTAGONIST, IN HEALTHY ADULT SUBJECTS
This early-stage study is testing a new medicine called REGN7999 in healthy people. We want to see if it's safe, how the body handles it, and if it could help with conditions where people have too much iron.
Healthy - R7999 being developed for the treatment of diseases associated with iron overload.Belgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Randomized Double-blind Controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of ExPEC9V and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older
This study looks at a new vaccine to prevent serious E. coli infections and a strong flu vaccine in people aged 65 and over. Researchers want to see how well they work, how safe they are, and if they can be given together.
Prevention of invasive extraintestinal pathogenic Escherichia coli (ExPEC) diseaseBelgium - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase I/II study to evaluate the feasibility, safety and preliminary efficacy of point-of-care manufactured anti-CD19 CAR T in subjects with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
This study is looking at a new treatment called BCN-CP01 for people with certain types of blood cancer (relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma) that have come back or not responded to previous treatments. It aims to see if the treatment is safe and if it helps patients get better.
relapsed/refractory chronic lymphocytic leukemiarelapsed/refractory small lymphocytic leukemiaBelgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study with a Long-Term Extension Treatment Period to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants with Early Alzheimer's Disease
This study is testing a new medicine, JNJ-63733657, for people with early Alzheimer's disease. Researchers want to see if it's safe and helps improve memory and thinking over two years, compared to a dummy drug.
Early Alzheimer's DiseaseBelgium - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1 Study of the SHP2 Inhibitor BBP-398 (formerly known as IACS-15509) in combination with the KRAS-G12C Inhibitor Sotorasib in Patients with Advanced Solid Tumors and a KRAS-G12C Mutation
This study is testing a new combination of two medicines for people with advanced cancers that have a specific genetic change (called KRAS-G12C). One medicine is new (BBP-398), and it's being given with an existing one (sotorasib) to see if they work better together.
Advanced or metastatic solid tumors with a KRAS-G12C mutation, Advanced or metastatic non-small cell lung cancer (NSCLC) with a KRAS-G12C mutation and who are KRAS-G12Ci naïveBelgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
ISIS 678354-CS6 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients with Severe Hypertriglyceridemia
This study is testing a new medicine, Olezarsen, for people with very high levels of a type of fat in their blood called triglycerides. We want to see if it helps lower these levels and prevent related health problems.
Severe hypertryglyceridemiaBelgium - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
Phase 1 study of NG-641 plus nivolumab (or standard of care PD-1) in metastatic or advanced epithelial tumours (NEBULA)
This study is looking into a new treatment called NG-641, used with an existing cancer medicine (nivolumab or similar), for people with advanced or spreading cancer. It's a very early-stage trial, focusing on safety and how the new treatment works in the body.
Metastatic cancer, Epithelial tumoursBelgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
I8F-MC-GPHJ: A Phase 3b, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide 2.4 mg in Adults Who Have Obesity or Overweight with Weight-Related Comorbidities
This study is comparing two medicines, Tirzepatide and Semaglutide, to see which is more effective and safer for helping adults with obesity or overweight, who also have other health issues, to lose weight. It's looking at how much weight people lose and other health changes.
ObesityOverweightBelgium - Ongoing, recruitingTherapeutic use (Phase IV)
A Phase 4, Randomized, Open-Label, Active-Controlled Study to Investigate the Efficacy and Safety of Switching From Weekly Dulaglutide to Weekly Tirzepatide in Adults With Type 2 Diabetes
This study is looking at how well a new medicine, Tirzepatide, works for adults with type 2 diabetes when they switch from another medicine called Dulaglutide. Researchers want to see if the new medicine helps lower blood sugar and improve other health markers like weight.
Type 2 DiabetesBelgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)
This study is looking at a new medicine called Rocatinlimab for adults with moderate to severe eczema. We want to see if it helps improve skin, reduce itching, and is safe over 24 weeks compared to a dummy medicine.
Atopic DermatitisBelgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1 (PH1)
This study, called ILLUMINATE-C, is looking at a new medicine called Oxlumo for people with a serious kidney and liver condition called Primary Hyperoxaluria Type 1 (PH1). It's a Phase 3 study to check if the medicine is safe and helps to reduce a harmful substance called oxalate in the body.
Primary Hyperoxaluria Type 1 (PH1)Belgium - Ongoing, recruitingPhase II and Phase III (Integrated)
Evasayil TM: A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome
This study is testing a new medicine, spesolimab, for Netherton syndrome. It's a trial where some people get the medicine and others get a dummy treatment (placebo) to see how well spesolimab works and if it's safe. We're looking at how it improves skin symptoms and overall well-being.
Netherton syndrome (NS)Belgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Pilot study RCT anti-NGF Adalimumab versus placebo in fasciotomy Dupuytren contracture
This study is testing a new medicine called Adalimumab for Dupuytren's disease, a hand condition. Researchers want to see if this medicine can help straighten fingers better than a dummy treatment after surgery. The main goal is to improve finger movement by at least 10 degrees.
Dupuytren DiseaseBelgium - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
Phase 1 study of NG-350A plus pembrolizumab in metastatic or advanced epithelial tumours (FORTIFY)
This study, called FORTIFY, is testing a new treatment called NG-350A along with an existing cancer drug, pembrolizumab. It's for adults with advanced or spreading cancers that start in the lining of organs, like skin or glands. This is an early-stage study to see if the treatment is safe.
Epithelial tumours, Metastatic cancerBelgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to evaluate efficacy and safety of secukinumab administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with polymyalgia rheumatica (PMR)
This study is testing a new medicine, secukinumab, for polymyalgia rheumatica (PMR). It compares secukinumab with a dummy treatment (placebo) alongside a common steroid medicine to see if it helps reduce symptoms and allows people to use less steroid medicine.
Polymyalgia RheumaticaBelgium - Ongoing, recruitingTherapeutic use (Phase IV)
A phase IV, randomized double blinded placebo-controlled study on the barrier restoring capacity of Dupilumab in type 2 airway disease: CRSwNP
This study is looking at how a medicine called Dupixent (Dupilumab) might help people with long-term stuffy nose and growths called nasal polyps. We want to see if it helps fix the natural barrier in the nose lining.
chronic rhinosinusitis with nasal polypsBelgium - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Study to Estimate the Effect of Multiple Doses of Carbamazepine on the PK of Single Dose Vepdegestrant in Healthy Adult Participants
This study is looking at how a common seizure medication, carbamazepine, affects a new breast cancer drug called vepdegestrant in healthy adults. It's an early-stage study to understand how these medicines interact in the body.
ER+/HER2 positive breast cancerBelgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
This study is testing a new medicine, astegolimab, for people with a lung condition called COPD. It wants to see if this medicine can help reduce flare-ups (exacerbations) of COPD and if it's safe to use. You might get the new medicine or a dummy medicine.
Chronic Obstructive Pulmonary Disease (COPD)Belgium - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Single-dose, Open-label, Randomized, Crossover Study to Assess the Relative Oral Bioavailability of a JNJ-77242113 Phase 3 Immediate-release Tablet Formulation with Respect to the Phase 2 Immediate-release Tablet Formulation and to Assess the Food Effect of a JNJ-77242113 Phase 3 Immediate-release Tablet Formulation in Healthy Participants
This study is looking at a new medicine called JNJ-77242113 for inflammatory conditions. It's comparing two versions of the tablet and seeing how food affects one of them. The aim is to understand how well the body absorbs the medicine.
Inflammatory ConditionsBelgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
This study is testing a new eye treatment called JNJ-81201887 for a condition called Geographic Atrophy (GA). GA is a serious eye problem linked to ageing that can cause blurry vision. Researchers want to see if this new treatment can slow down the worsening of GA.
Geographic AtrophyBelgium